Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment

Introduction: The structured Benefit–risk Action Team (BRAT) approach aims to assist healthcare decision makers in treatment assessments. We applied BRAT to compare the benefit–risk profile of ranibizumab 0.5 mg versus laser photocoagulation for the treatment of diabetic macular oedema (DMO). Method...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Endocrinol
Main Authors: Ziemssen, Focke, Cruess, Alan, Dunger-Baldauf, Cornelia, Margaron, Philippe, Snow, Howard, Strain, William David
Formato: Artigo
Idioma:Inglês
Publicado: Touch Medical Media 2017
Assuntos:
Diabetic Macular Oedema
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813472/
https://ncbi.nlm.nih.gov/pubmed/29632615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2017.13.02.91
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares